Ring Therapeutics Presents Preclinical Data on Anellogy™ Platform at the 31st Annual European Society of Gene & Cell Therapy Conference

Data further validates the AnelloVector™ platform as the first gene delivery vector system based on the human commensal anellovirus

CAMBRIDGE, Mass., Oct. 22, 2024 — Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today unveiled preclinical data showcasing successful vectorization of its anellovirus-based vectors beyond the wild-type genome capacity, with durable in vivo gene expression sustained over a 12-month period via subretinal administration. The data will be showcased in a poster presentation at the 31st Annual European Society of Gene & Cell Therapy (ESGCT), demonstrating the promise AnelloVector™ viral vectors hold as the future of viral vectors.

“I am incredibly proud of the significant milestone our team at Ring has achieved demonstrating not only successful expansion of the AnelloVector™ therapeutics’ payload capacity, but also achieving durable gene expression in vivo, sustained over 12-months,” said Tuyen Ong, MD, MBA, Chief Executive Officer of Ring Therapeutics and CEO-Partner at Flagship Pioneering. “By expanding the payload capacity of AnelloVector™ viral vectors, we are unlocking new therapeutic possibilities, leveraging their inherent immune compatibility and targeted tropism to potentially reach a broader patient population. These findings bring us one step closer to advancing our platform into clinic trials and underscore our commitment to improving patient outcomes by delivering life-changing genetic medicines.”

Poster details and key highlights below:

Title: ANELLOVECTOR™ Viral Vectors: encapsidating anellovirus-based vectors beyond the wild-type genome capacity and demonstrating 12-month durable expression of an eGFP transgene post subretinal administration

Poster number: P0149

Presenter: Joseph Cabral, Ph.D.

Production of AnelloVector™ therapeutics is enabled by Ring’s Self-Amplifying Trans-complementation of a Universal Recombinant aNellovector™ (SATURN) system.
Leveraging this system, we demonstrated that AnelloVector™ viral vectors are capable of packaging vector genomes ranging up to 5.0kb, representing up to 65% beyond the wild-type genome capacity.
An eGFP transgene verified that the AnelloVector™ viral vector produced durable in vivo gene expression in a mouse eye for 12 months following subretinal administration.
These data underscore the promise that AnelloVector™ therapeutics will be safe, durable, redosable, and potent, helping to expand the reach of programmable medicines.